72 filings
Page 3 of 4
8-K
763zev
4 Jun 21
Submission of Matters to a Vote of Security Holders
7:00am
8-K
tmrywa8f8umgr jhe5
19 May 21
Regulation FD Disclosure
5:00pm
8-K
xxnvfdd si8vyc
7 May 21
Business Highlights and 2021 Anticipated Milestones
7:00am
8-K
81qhf4gpq
15 Apr 21
Other Events
7:00am
8-K
ngtht2psfm60tb8
18 Mar 21
Sutro Biopharma Reports Full Year 2020 Financial Results
7:00am
8-K
gz3ouhm6lfbvnwi9hb
9 Dec 20
Entry into a Material Definitive Agreement
4:38pm
8-K
7yby9k
7 Dec 20
Regulation FD Disclosure
3:45pm
8-K
06bbd
4 Dec 20
Sutro Biopharma Announces Encouraging Interim Data on STRO-002 Phase 1 Dose-Escalation Study for Patients with Ovarian Cancer
12:00am
8-K
tu4l27wrnwde
1 Dec 20
Departure of Directors or Certain Officers
7:09am
8-K
se5v5x7z s4oinq
5 Nov 20
Sutro Biopharma Reports Third Quarter 2020 Financial Results
7:05am
8-K
7ankk ua5c1h
9 Sep 20
Other Events
5:23pm
8-K
3hc kd0x0rrfesx0zlkb
4 Sep 20
Entry into a Material Definitive Agreement
12:00am
8-K
yh65klmsjtsfvec292m0
6 Aug 20
Sutro Biopharma Reports Second Quarter 2020 Financial Results
7:03am
8-K
spkwlr3
15 Jun 20
Regulation FD Disclosure
7:21am
8-K
o6majx31l2jg1
5 Jun 20
Submission of Matters to a Vote of Security Holders
4:43pm
8-K
mghjbjmrubq8o
12 May 20
Entry into a Material Definitive Agreement
5:14pm
8-K
7j6j1w80r7jjqa e7x
11 May 20
Sutro Biopharma Reports First Quarter 2020 Financial Results
4:27pm
8-K
vl7 2m9y7k
27 Apr 20
Sutro Biopharma Announces Encouraging Interim Phase 1 Clinical Data for a Dose Escalation Study of STRO-002 Antibody-Drug Conjugate in Ovarian Cancer
8:00am
8-K
hpfg 6zut162ufycyyrw
16 Mar 20
Sutro Biopharma Reports Full Year 2019 Financial Results
6:04am
8-K
q4c 7jkxkmbp
3 Mar 20
Entry into a Material Definitive Agreement
12:00am